Evaluation of the radioprotective properties of recombinant flagellin when used alone or in combination with interleukin-1 beta



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Research objective. To evaluate the radioprotective effectiveness of recombinant flagellin when used alone or in combination with interleukin-1 beta for prophylactic or therapeutic effect on animals. Materials and methods. The effect of hybrid flagellin FliC Salmonella typhimurium and human interleukin-1β (Institute of Highly Pure Biopreparations, Saint Petersburg, Russia) on the 30-day survival of male mice exposed to lethal doses of X-ray radiation was studied. Survival of irradiated animals was analyzed by Kaplan-Meier method. Results. The preventive use of flagellin had a protective effect on the 30-day survival of mice irradiated with lethal doses of X-rays. Compared with the irradiated control, the administration of flagellin (1 mg/kg or 2 mg/kg) prior to X-ray exposure (7.5 Gy, 8.0 Gy or 8.5 Gy) increased the animal survival rate to 67-87%. Complex preventive administration of flagellin (1 mg/kg) and interleukin-1 beta (50 μg/kg) provided a 100% survival rate of the irradiated mice. Separate use of drugs was also effective; 92.8% of mice survived when flagellin was administered prior to irradiation and interleukin after. Conclusion. Recombinant flagellin is a promising candidate product for designing new generation of domestic radiation countermeasures, including combinations with interleukin-1 beta.

Full Text

Restricted Access

About the authors

E V Murzina

S.M. Kirov Military Medical Academy

G A Sofronov

S.M. Kirov Military Medical Academy; Institute of Experimental Medicine

A S Simbirtsev

Institute of Experimental Medicine; Institute of Experimental Medicine; Research Institute of Highly Pure Biopreparations

N V Aksenova

S.M. Kirov Military Medical Academy

O M Veselova

S.M. Kirov Military Medical Academy

A M Ischenko

Research Institute of Highly Pure Biopreparations

References

  1. Рождественский Л.М. Актуальные вопросы поиска и исследования противолучевых средств // Радиационная биология. Радиоэкология. - 2013. - Т. 53. - № 5. - С. 513-520. [Rozhdestvenskiy LM. Aktual’nye voprosy poiska i issledovaniya protivoluchevykh sredstv. Radiats Biol Radioecol. 2013;53(5):513-520. (In Russ.)]
  2. Singh VK, Romaine PL, Seed TM. Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile. Health Phys. 2015;108(6):607-630. doi: 10.1097/HP.0000000000000279.
  3. Kamran MZ, Ranjan A, Kaur N, et al. Radioprotective Agents: Strategies and Translational Advances. Med Res Rev. 2016;36(3):461-493. doi: 10.1002/med.21386.
  4. Гребенюк А.Н., Аксенова Н.В., Петров А.В., и др. Получение различных вариантов рекомбинантного флагеллина и оценка их радиозащитной эффективности // Вестник Российской военно-медицинской академии. - 2013. - Т. 43. - № 3. - С. 75-80. [Grebenyuk AN, Aksenova NV, Petrov AV, et al. Expression of different variants of recombinant flagellin and study of their radioprotective efficacy. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2013;43(3):75-80. (In Russ.)]
  5. Гребенюк А.Н., Легеза В.И. Противолучевые свойства интерлейкина-1. - СПб.: Фолиант, 2012. [Grebenyuk AN, Legeza VI. Protivoluchevye svoystva interleykina-1. Saint Petersburg: Foliant; 2012. (In Russ.)]
  6. Боровиков В.П. Популярное введение в современный анализ данных в системе Statistica. - M.: Горячая линия-Телеком, 2013. [Borovikov VP. Populyarnoe vvedenie v sovremennyy analiz dannykh v sisteme STATISTICA. Moscow: Goryachaya liniya-Telekom; 2013. (In Russ.)]
  7. Мурзина Е.В., Софронов Г.А., Аксенова Н.В., и др. Экспериментальная оценка противолучевой эффективности рекомбинантного флагеллина // Вестник Российской военно-медицинской академии. - 2017. - Т. 59. - № 3. - С. 122-128. [Murzina EV, Sofronov GA, Aksenova NV, et al. Experimental estimation of the radioprotective efficiency of recombinant flagellin. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2017;59(3):122-128. (In Russ.)]
  8. Симбирцев А.С. Интерлейкин-1. Физиология, патология, клиника. - СПб.: Фолиант, 2011. [Simbirtsev AS. Interleykin-1. Fiziologiya, patologiya, klinika. Saint Petersburg: Foliant; 2011. (In Russ.)]
  9. Vijay-Kumar M, Aitken JD, Sanders CJ, et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol. 2008;180(12):8280-8285. doi: 10.4049/jimmunol.180.12.8280.
  10. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320(5873):226-230. doi: 10.1126/science.1154986.
  11. Krivokrysenko VI, Toshkov IA, Gleiberman AS, et al. The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates. PLoS One. 2015;10(9):e0135388. doi: 10.1371/journal.pone.0135388.
  12. Singh VK, Garcia M, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int J Radiat Biol. 2017;93(9):870-884. doi: 10.1080/09553002.2017.1338782.
  13. Krivokrysenko VI, Shakhov AN, Singh VK, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther. 2012;343(2):497-508. doi: 10.1124/jpet.112.196071.
  14. Lopez-Yglesias AH, Zhao X, Quarles EK, et al. Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway. J Immunol. 2014;192(4):1587-1596. doi: 10.4049/jimmunol.1301893.
  15. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappa B signaling. Immunol Rev. 2006;210:171-186. doi: 10.1111/j.0105-2896.2006.00375.x.
  16. Chen H, Wang ZD, Chen MS, et al. Activation of Toll-like receptors by intestinal microflora reduces radiation-induced DNA damage in mice. Mutat Res Genet Toxicol Environ Mutagen. 2014;774:22-28. doi: 10.1016/j.mrgentox.2014.09.001.
  17. Li W, Ge C, Yang L, et al. CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro. Int J Biol Macromol. 2016;82:97-103. doi: 10.1016/j.ijbiomac.2015.10.033.
  18. Wang Z-D, Qiao Y-L, Tian X-F, et al. Toll-like Receptor 5 Agonism Protects Mice from Radiation Pneumonitis and Pulmonary Fibrosis. Asian Pac J Cancer Prev. 2012;13(9):4763-4767. doi: 10.7314/apjcp.2012.13.9.4763.
  19. Zhou S-X, Li F-S, Qiao Y-L, et al. Toll-like Receptor 5 Agonist Inhibition of Growth of A549 Lung Cancer Cells in Vivo in a Myd88 Dependent Manner. Asian Pac J Cancer Prev. 2012;13(6):2807-2812. doi: 10.7314/apjcp.2012.13.6.2807.
  20. Toshkov IA, Gleiberman AS, Mett VL, et al. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation. Radiat Res. 2017;187(5):570-580. doi: 10.1667/RR14514.1.
  21. Liu Z, Lei X, Li X, et al. Toll-like receptors and radiation protection. Eur Rev Med Pharmacol Sci. 2018;22(1):31-39. doi: 10.26355/eurrev_201801_14097.
  22. Brackett CM, Kojouharov B, Veith J, et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci U S A. 2016;113(7):E874-883. doi: 10.1073/pnas.1521359113.
  23. Kojouharov BM, Brackett CM, Veith JM, et al. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. 2014;5(3):802-814. doi: 10.18632/oncotarget.1773.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Murzina E.V., Sofronov G.A., Simbirtsev A.S., Aksenova N.V., Veselova O.M., Ischenko A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies